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Abstract
The design of selective drugs and combinatorial drug treatments are two of the main
focuses in modern pharmacology. In this study we use a mathematical model of chimeric
ligand-receptor interaction to show that the combination of selective drugs is synergistic in
nature, providing a way to gain optimal selective potential at reduced doses compared to
the same drugs when applied individually. We use a cell population model of proliferating
cells expressing two different amounts of a target protein to show that both selectivity and
synergism are robust against variability and heritability in the cell population. The reduction
in the total drug administered due to the synergistic performance of the selective drugs can
potentially result in reduced toxicity and off-target interactions, providing a mechanism to
improve the treatment of cell-based diseases caused by aberrant gene overexpression,
such as cancer and diabetes.
Introduction
The field of modern pharmacology aims to develop novel approaches to improve disease treat-
ment, reduce side effects, minimize costs and enhance the efficiency of targeted therapy. These
major challenges require a rational design of novel drugs and improved treatment strategies. In
this direction, two of the main approaches currently being pursued involve the development of
selective drugs and the design of optimal drug combination therapies.
Drug selectivity can be defined as the ability of a compound to exhibit enhanced effect to-
wards a particular cell population in preference to others. To achieve that, a drug must be de-
signed to target specific cellular components that are differentially expressed in two cell types.
In the context of diseases that involve cells overexpressing certain genes, such as oncogenes in
cancer [1], this targeting potential can be used to selectively affect only cells with increased lev-
els of the overexpressed protein. Once selectivity is achieved, the drug can be designed to either
restore normal cellular function when possible, or to trigger apoptosis of the unhealthy cells
without harming the healthy cellular environment. In general, selective drugs are composed of
a targeting element (TE) that recognizes and binds to the target protein, and an activity element
(AE) that is directed towards the selectively targeted cells. Many of these synthetic chimeric
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compounds have shown good in vivo performance, and several of them have been approved by
the FDA or currently undergoing clinical trials [2–15].
On the other hand, drug combination therapies have shown enhanced efficiency compared
to individual drug therapy in many diseases [16], including cancer [17, 18] and HIV’s [19].
The interaction between drugs in multicomponent therapies is a complex and multi-scale
problem [20] that requires full characterization of the direct and indirect molecular aspects of
the interaction, which are often unknown. Due to this, experimental studies and discoveries of
successful drug combinations are often based on empirical intuition and trial-and-error ap-
proaches. In general, drug interactions can be classified based on their effect when combined,
compared to their effect when applied alone. Drugs that do not interact with each other, or are
mutually exclusive by competing for the same target are considered as additive [22]. This basi-
cally means that the lower concentration which produces a certain effect corresponds to the
most potent drug, and there is no gain due to the combination of the two drugs. On the other
hand, antagonism occurs when one of the drugs mitigates or counteracts the action of the
other, i.e, the combination is always less effective than the single agents at the same concentra-
tion. Finally, synergism occurs when the combination of both drugs is more effective than each
agent separately at the same total concentration, i.e., one of the agents enhances the actions of
the other [21]. This can occur either via direct interaction, i.e, one drug increases the bioavail-
ability of the other, or indirectly, i.e, the two drugs cooperate on targets on the same or different
pathways involved in the same process [23]. Thus, the total concentration of drug administered
to achieve a certain effect is reduced, which potentially also reduces side effects, drug resistance
and undesired off-target interactions.
In the context of selective drugs, synergism and antagonism can be also defined in terms of
the enhanced or reduced selective potential of the two drugs when combined [24], i.e, their
ability to target selectively a specific cell population, compared to their selective potential when
applied individually. In this way, two drugs are synergistic if their combination is more selec-
tive than the two drugs acting alone at the same total concentration. Here, we explore the
mechanism of interaction between selective drugs in combination from a theoretical perspec-
tive. To do that, we develop a population model where two sets of cells expressing different lev-
els of a target molecule are treated with different concentrations of two drugs simultaneously.
In principle, these two drugs can be monomeric non-selective ligands (i.e., they do not differen-
tiate between healthy and unhealthy cells), or chimeric ligands, composed of an AE and linked
to a TE, allowing them to selectively target unhealthy cells, leaving the healthy
environment undamaged.
Two different approaches are taken into account: first, we analyze the effect of combinations
of two different chimeric ligands when applied simultaneously to an heterogeneous population
of cells; next, we combine the effect of individual chimeric drugs based on the Loewe additivity
model [22]. Both models predict that drug combination of selective drugs is synergistic in
terms of their selective potential. Finally, we introduce phenotypic inheritance in the cell popu-
lation to show that both selectivity and synergism also occur in a context where the amount of
target proteins of the daughter cells depends on the mother cell, such as in diseases caused by
mutations in specific genes. Our results show that the concentration to obtain a desired selec-
tivity can be minimized by simultaneous treatment of selective drugs.
Models
To analyze the effect of selective drug combinations in a multicellular approach, we develop a
mathematical framework where we allow two asynchronous populations of cells with two dis-
tinct average number of target molecules to proliferate for a given time. Cells are treated with
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different concentrations of monomers and chimeric drugs alone or in combination, to then
monitor and compare the dynamics of proliferation of the two cell populations. The dynamics
of the effect of chimeric drugs at the cellular level is calculated based on a chemical kinetics
model for the ligand-receptor interaction [25]. The model used is an extension of our previous
contribution to the study of the dynamics of chimeric ligands, where we develop a mathemati-
cal framework to predict the selective potential of chimeric drugs, based on the affinity of both
AE and TE subunits of the ligand towards their targets (activity element receptor, AER, and
targeting element receptor, TER, respectively), the concentration of the target molecules and
the linker length between AE and TE in the chimera [25]. The model is rewritten to take into
account the simultaneous interaction of two chimeric ligands, resulting in the following set of
interactions:
Ri þ Lj Ð
koni; j
k
off
i; j
Ci;j ð1Þ
C1;j þ R2 Ð
kc
2;j
ku
2; j
C3;j ð2Þ
C2;j þ R1 Ð
kc
1;j
ku
1; j
C3;j ð3Þ
Ci;j;C3;j !
kei;j ;k
e
3; j
∄ ð4Þ
where Ri corresponds to the i receptor (i = 1,2) and Lj corresponds to each of the two different
ligands (j = 1,2) used in the combined treatment. Each ligand Lj is composed of a AE and TE,
and it can bind to R1 or R2 via reaction 1 to give an intermediate complex Ci,j (Fig. 1A–C).
These intermediate complexes facilitate reactions 2 and 3 by originating a local concentration
of the free subunit of the ligand Lj in the vicinity of the complementary receptor, to generate
the complex C3,j (Fig. 1D). The coupling (kci;j) rate constants in reaction 2 and 3 are calculated
as follows:
kci;j ¼
1
kdiffi
þ 1
kon0i;j
 !1
ð5Þ
where the diffusive rate constant kdiffi is modulated by the diffusion Di of the receptors Ri at the
membrane as [26, 27]:
kdiffi ¼
2pðPDiÞ
A  log ðbi=aÞ
ð6Þ
being A the average cell surface area, bi ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A=ðpRiÞ
p
corresponds to half the average distance
between R1 and R2, and a is the linker length. Effective afﬁnity and dissociation rates for the re-
actions that take place at the membrane are calculated as [26]:
kon
0
i;j ¼
koni;j
Nav  Vi
ð7Þ
kui;j ¼ ð1 gi;jÞkoffi;j ð8Þ
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where Nav is Avogadro’s number and Vi = A  (hi + a) is the effective reaction volume for the
second binding event, assumed as a spherical gasket above the cell surface where the free sub-
unit gets distributed after the ﬁrst binding event (see [25]), being hi the height of Ri above the
cell surface. gi;j ¼ kon0i;j =ðkdiffi þ kon0i;j Þ corresponds to the capture probability factor for receptor
Ri and ligand Lj, explained in detail in [26].
For a given constant concentration of both ligands Lj, the equations are solved for each indi-
vidual cell in the population, based on its amount of R1 and R2 receptors, identified as TER and
AER, respectively. The maximum value of AER-AE complexes formed in each cell is then cor-
related with the physiological response produced by the AE using experimental dose-response
curves (this correlation is a multi-step process explained in detail in Ref. [25]). Typical dose-
response curves are often fitted to a four-parameter sigmoidal [25], such as:
RðLÞ ¼ A D
1þ ðL=EC50ÞB
þ D ð9Þ
where the physiological response R(L) for a given drug concentration L is characterized by its
maximal D and minimal A asymptotes, B is the slope parameter of the curve, and EC50 is the
Fig 1. Scheme of the model for the simultaneous interaction of two chimeric ligands with their corresponding receptors. (A) Each one of the ligands
Lj consists of two subunits which can interact with their corresponding receptors to form intermediate complexesCi,j. (B,C) This first binding event induces an
increase in the local concentration of the free subunit of the ligand facilitating the interaction with its corresponding receptor to form complexC3,j (D).
doi:10.1371/journal.pone.0117558.g001
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half-maximal effective concentration of the ligand, that is, the inﬂection point of the curve.
S1A Fig. shows a schematic representation of the workﬂow used to solve the model equations
and obtain the dynamics of growth of the heterogeneous cell population.
As a numerical solution, the model is informed with data from a synthetically designed chi-
meric ligand composed of the Epidermal Growth Factor (EGF) as TE and different mutants of
Interferon alfa-2a (IFNα-2a) as AE [15]. Thus, the apoptotic effect triggered by IFNα-2a stimu-
lation is directed towards cells overexpressing the Epidermal Growth Factor Receptor (EGFR).
The physiological response of the cells to the treatment corresponds to the apoptotic effect in-
duced by IFNα-2a, measured experimentally as the percentage of surviving cells after 60 hours
of treatment.
Since EGFR is an oncogene overexpressed in a number of tumor cells [28], this chimera can
be potentially used to selectively target cancer cells without affecting the healthy surrounding
tissue. Different mutants of the IFNα-2a molecule are tested as monomers (Mwt,M1,M2 and
M3), and as AE’s in chimeric configuration, identified here as Chwt for the chimera composed
of the wild type version of the IFNα-2a linked to EGF, and Ch1, Ch2 for the experimentally
available mutants of IFNα-2a with reduced affinity towards the IFNα-2a receptor linked to the
targeting element EGF [15]. Other potential chimeras composed of EGF linked to IFNα-2a
mutants with decreasing affinity towards the AER combined with EGF, named Ch3 and Ch4,
are included in the analysis (Table 1 shows the dissociation constants for each IFN monomer).
To mimic the experimental conditions, cells in the population are allowed to proliferate for
60 hours in the presence of the drug treatment, and the physiological response of each cell to
the treatment depends on the amount and efficiency of each ligand, the amount of TER and
AER receptors expressed, and the exposure time to treatment. Given that the physiological re-
sponse of the cells is apoptosis, we set the decision between survival or death for each cell in the
population as follows: for a given physiological response (0< R(L)< 1), the probability of un-
dergoing apoptosis at every time point is computed as θ = (1 − R(L))Δt/T, being T the total
length of the experiment and Δt the time step in the simulation. Then, a random number
(0< γ< 1) from a uniform distribution is assigned for each cell in the population and
Table 1. Parameters used in the population model. Values of IFNα-2a (AE) dissociation rates (kD),
corresponding to IFNα-2a-IFNR wild type and mutants of IFNα-2a, from recent publications [15, 39] and
theoretical ligands (M3 and M3). Mean values of EGF and IFN receptors expressed by Daudi and Daudi-
EGFR cells, extracted from [15].
Parameter Value Units Reference
kD Mwt 3 nM Ref. [39]
kD M1—K133A 26 nM Ref. [39]
kD M2—R144A 120 nM Ref. [39]
kD M3 240 nM theoretical
kD M4 480 nM theoretical
kD EGF 2.47 nM theoretical
[EGFR]healthy 22 molecules Ref. [15]
[IFNR]healthy 2800 molecules Ref. [15]
[EGFR]unhealthy 5640 molecules Ref. [15]
[IFNR]unhealthy 3600 molecules Ref. [15]
# of cells at t = 0 100 cells theoretical
Average cell cycle 27.5 hours Ref. [29, 40]
Total time 60 hours theoretical
doi:10.1371/journal.pone.0117558.t001
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compared to the value of θ at every time step. If γ θ, the cell survives. On the contrary, if γ<
θ, then the cell dies and it is no longer considered in the simulation.
A cell division occurs when the age of a given cell reaches the numerical value for the cell
cycle length assigned to that particular cell. This value is obtained from a gamma distribution
with mean m = 27.5 hours [29, 30] and standard deviation of 2 hours. The amount of surface
receptors are also gamma distributed [31], with a mean value obtained from experimental data
[15] (see Table 1) and a coefficient of variation of 0.3, to mimic cell-to-cell variability in both
populations. Mean values of the final cell numbers are obtained from 10 independent runs of
the model. Numerical solution of the model equations and other calculations are performed
using a in-house Matlab script (code available upon request).
Results
Selectivity of chimeric drugs versus monomers in a cell population
The model described above is used to illustrate the effect of monomers versus chimeric ligands
in a heterogeneous cell population. Fig. 2 illustrates the dynamics of growth of healthy (blue
curve) and unhealthy (red curve) cell populations under nonselective monomers versus selec-
tive chimeric ligand treatment. To characterize and compare its selective potential, we define a
threshold based on the amount of cells of both populations that remain after 60 hours of treat-
ment (i.e., the duration of the experiments in [15], where the dose-response curves and other
experimental data are obtained). Thus, a given treatment is considered as efficient when the
number of unhealthy cells does not increase, while the population of healthy cells grows to at
least 80% of its potential size. These two threshold values are marked in Fig. 2A–I as dashed
red and blue horizontal lines for the unhealthy and healthy cells, respectively. These threshold
values will be used to categorize the selective potential of a given treatment.
Low concentrations ofMwt are harmless to both cell populations, which can grow exponen-
tially (Fig. 2A). Intermediate concentrations (Fig. 2B) have a much stronger effect in healthy
cells than in unhealthy cells, due to higher resistance to IFNα-2a treatment in the unhealthy
cell population (reported experimentally in [15], where authors hypothesized that this effect is
mainly due to the anti-apoptotic potential of the EGFR overexpression [32] that may counter-
act the effect of IFNα-2a stimulation). Higher concentrations of the monomer are able to re-
duce the number of unhealthy cells in the system, but affecting the healthy population even
more (Fig. 2C). This type of response is similar for all mutants of the monomer of IFNα-2a, as
shown in the S2 Fig.
On the other hand, chimeric ligands show enhanced effect in cells overexpressing EGFR.
The dynamics of Chwt ligand treatment, composed of EGF linked to wild type IFNα-2a, is
shown in Fig. 2D–F. Low concentrations do not affect the growth rate of both cell populations.
Intermediate and high values of chimeric ligand affect both healthy and unhealthy cells, reduc-
ing both cell populations simultaneously.
Optimal treatment can be achieved by the chimeric ligand composed of EGF linked to a mu-
tant of IFNα-2a with reduced affinity towards the IFN receptor, as shown in Fig. 2G–I. Low
concentrations of ligand Ch2 do not affect any of the populations, while intermediate values do
allow the healthy cells to proliferate and prevent the unhealthy cell population to expand in
size. Again, high concentrations of the ligand start to affect the healthy population that cannot
grow above its 80% potential size. Dynamics for other chimeric ligands are plotted in S3 Fig.
Fig. 2J–M plots the amount of TER and AER for each cell of the healthy (blue) and unhealthy
(red) population before treatment (Fig. 2J) and after 60 hours of treatment with intermediate
concentrations ofMwt (Fig. 2K), Chwt (Fig. 2L) and Ch2 (Fig. 2M). Interestingly, despite the fact
that the apoptotic potential of the monomers and chimeras directly depends on the amount of
Synergistic Interaction between Selective Drugs
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Fig 2. Dynamics of the cell populations after individual drug treatment. (A–C) Numerical solution of the
model equations showing the time evolution of healthy (blue line) and unhealthy (red line) cells after
treatment with low, intermediate and high concentrations of theMwtmonomer. (D–F) Time evolution after
treatment with different concentrations of Chwt. (G–I) Time evolution after treatment with different
concentrations of Ch2, which at intermediate values is able to achieve the threshold of 80% survival of healthy
Synergistic Interaction between Selective Drugs
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AER expressed by each individual cell, the model predicts that a number of cells with high val-
ues of AER does not undergo apoptosis after 60 hours of treatment. This is due to the fact that
the physiological response of a given cell depends on the time that it has been under treatment
and, since cells are continuously being born during the simulation, at t = 60 hours some recently
born cells may not have been enough time under the influence of the drug to trigger apoptosis.
The above data evidences that selectivity in terms of the threshold of 80% can only be
achieved using low affinity mutants of the AE subunit of the chimera, which are only efficient
at very high concentrations of ligand (around 2 nM concentration for Ch2). This concentration
representes a 4X increase compared to the concentration for Chwt = 0.5nM, which is the mini-
mum concentration required to prevent the expansion of the unhealthy cell population at the
expense of affecting strongly the healthy cells. This increase is also reported experimentally in
[15], where the minimum concentration of Ch2 to prevent the unhealthy cell population to ex-
pand leaving the 80% of the healthy surrounding undamaged is 1.5nM, 3 times higher than the
value of 0.5nM of Chwt that prevents the growth of the unhealthy cell population. Unfortunate-
ly, this higher doses of drug required to achieve selectivity can result in the emergence of other
potential undesired effects, such as toxicity, or increased off-target interactions [33]. Therefore,
strategies to reduce the total drug concentration for a given selective effect are relevant. In the
next section, we show how combinations of selective chimeric ligands can reduce the concen-
tration of total drug administered maintaining the selective potential.
Synergistic interaction of selective chimeric drugs
Mutant monomers of the same molecule act against the same target, therefore they behave as
mutually exclusive and their interaction when combined is additive by definition. In this way,
the lowest concentration to obtain a given effect always corresponds to the monomer with
stronger binding affinity towards its receptor. Fig. 3A–C corresponds to simultaneous treat-
ment of a fixed concentration ofMwt = 0.5nM with the minimal concentration of the mutants
of IFNα-2a able to affect at least 20% of the unhealthy cells. According to their additive interac-
tion, none of the potential combinations tested allows us to reduce the total drug concentration
of IFNα-2a administered. In addition, none of the multiple combinations tested is able to miti-
gate the strong effect that the monomers exhibit towards the healthy cell population, as illus-
trated also in the next section.
Multi-drug treatment using selective drugs is shown by Fig. 3D–I, where we plot the dynam-
ics of the two cell populations at the minimal concentration of total drug required to achieve
the selectivity threshold for different combinations of the chimeras. Combinations of the poor-
ly selective Chwt with chimeras Ch2, Ch3 and Ch4 are able to mitigate the expansion of the un-
healthy cell population while meeting the 80% survival threshold of the healthy cells
(Fig. 3D–F). The threshold is also achieved when combining the rest of the chimeras with Ch1,
as shown in Fig. 3G–I.
Bars in each panel represent the minimal concentration of total drug to achieve the thresh-
old of selectivity for each combination of ligands, compared to the same ligands as single treat-
ment. We observe a slight reduction in the total concentration used for the combinatorial
cells, while the unhealthy cells are maintained. Solid line and error bars correspond to the average and
standard deviation of 10 independent runs of the model. (J–M) Distribution of the AER and TER receptors for
the two cell populations at (J) initial conditions, and after 60 hours of treatment with (K)Mwt = 0.52 nM, (E)
Chwt = 0.2 nM and (M) Ch2 = 2.5 nM (i.e, same concentrations of Fig. 2B,E,H, respectively) Each dot
corresponds to a cell in the population. Notice thatMwt treatment affects mainly the unhealthy cells (blue line,
B,C), whileCh2 treatment shows a greater effect on the unhealthy population (red line, H–I).
doi:10.1371/journal.pone.0117558.g002
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treatment compared to the individual treatment (values for the percentage of each reduction in
the total concentration at threshold are listed in Table 2). Overall, the gain in performance of
the dual treatment is more evident when combining a poorly selective ligand as Ch1 with a low
affinity but highly selective chimera, such as Ch3. In this situation, we can achieve the threshold
of optimal selectivity with a 50% reduction in the total drug concentration administered, com-
pared to the concentration of Ch3 as individual treatment.
The effect of combinatorial treatment can be estimated based on the
effect of single treatment strategies
Detailed analysis of the drug interaction for each combination of two given ligands, as per-
formed in the previous section, requires extensive computational resources. To overcome this,
we use an additional approach to calculate the effect of a combination of drugs based on their
Fig 3. Synergistic performance of selective ligands. (A–C) Numerical solution of the model equations
showing the time evolution of healthy (blue line) and unhealthy (red line) cells after treatment with different
combinations of monomers, at the minimal concentration required to affect 20% of the unhealthy cell
population. (D–F) Time evolution of different combinations of Chwt with other chimeric ligands at the minimal
concentration required to achieve the threshold for selectivity. (G–I) Time evolution of different combinations
of Ch1 with other chimeric ligands at the minimal concentration required to achieve the threshold for
selectivity. Bars in each figure correspond to the minimal concentration for the threshold for single treatment
and dual treatment with the chimeras used in each panel.
doi:10.1371/journal.pone.0117558.g003
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effect when applied individually, using the following equation [22]:
I ¼ Lc;1
L1
þ Lc;2
L2
ð10Þ
where Lc,1 and Lc,2 correspond to the concentrations of the two drugs that produce a given
effect when applied together, and L1 and L2 are the concentrations that induce the same effect
when applied alone. The interaction index I depends on the type of interaction between the
two drugs: synergistic (I< 1) additive (I = 1) or antagonistic (I> 1). In our particular case,
since both ligands share common binding sites (i.e., they are mutants of the same molecule
with reduced afﬁnity), they behave as mutually exclusive and therefore, they follow the princi-
ple of Loewe additivity so the interaction index I in Eq. 10 is set to 1 [22] (a detailed analysis of
the general equation for drug interaction in conditions of drug additivity, synergy or antago-
nism can be found as S1 Text).
Next, the Loewe additivity model is applied to drugs that induce a typical dose-response
curve [25], as described in Eq. 9. Thus, we solve Eq. 9 for L and substitute into Eq. 10 for both
ligands (L = L1 and L = L2), to obtain:
1 ¼ Lc;1
EC50;1
RðLc;1; Lc;2Þ  D1
A1  RðLc;1; Lc;2Þ
 !ð1=B1Þ
þ Lc;2
EC50;2
RðLc;1; Lc;2Þ  D2
A2  RðLc;1; Lc;2Þ
 !ð1=B2Þ
ð11Þ
This equation can be solved numerically to obtain the physiological response R(Lc,1, Lc,2) for
each potential combination of Lc,1 and Lc,2. The typical shape of the curve is shown in S4A Fig.
Therefore, Eq. 11 allows us to calculate directly the effect of the two drugs when applied
simultaneously, significantly reducing the computational cost of the process. S5 Fig. plots the
dynamics of several combinations of monomers and chimeras using this method (to be com-
pared with Fig. 3, computed using the simultaneous drug stimulation of the system to show
that both methods produce equivalent results). This simplified method allows us to compute
the effect of any combination between two given drugs to develop isobolograms representing
the final number of cells, after 60 hours of combined treatment for each combination of mono-
mers (Fig. 4A–B) and chimeras (Fig. 4D–E).
Finally, to compare the selective effect of multiple combination of ligands, we define the
performance P(Lc,1, Lc,2) of a given treatment as:
PðLc;1; Lc;2Þ ¼ Nf ðLc;1; Lc;2Þhealthy  Nf ðLc;1; Lc;2Þunhealthy ð12Þ
where Nf ðLc;1; Lc;2Þhealthy and Nf ðLc;1; Lc;2Þunhealthy correspond to the ﬁnal number Nf of healthy
and unhealthy cells respectively, after 60 hours of combined treatment (i.e., the ﬁnal point of
Table 2. Reduction in concentration at threshold for optimal selectivity. Percentage of reduction of
total drug concentration of combinatorial treatment versus single drug treatment for different selective
drug combinations.
Single drug Drug combination Reduction percentage
Ch1 = - Chwt + Ch1 = - -%
Ch2 = 2.2 Chwt + Ch2 = 2.0 7%
Ch3 = 4.2 Chwt + Ch3 = 3.3 22%
Ch4 = 10.1 Chwt + Ch4 = 8.6 14%
Ch2 = 2.4 Ch1 + Ch2 = 1.6 33%
Ch3 = 4 Ch1 + Ch3 = 2.3 42.5%
Ch4 = 10.1 Ch1 + Ch4 = 5.3 47.5%
doi:10.1371/journal.pone.0117558.t002
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the curves in Fig. 3) normalized to obtain values for the performance P(Lc,1, Lc,2) between −1
(minimal selectivity of treatment, i.e., 0% survival of the healthy cells) and 1 (optimal selectivi-
ty, i.e.,80% survival of healthy and no growth in the unhealthy cell population). A workﬂow
scheme of this approach is shown in S1B Fig.
Fig. 4A–B illustrates the isobolograms for any concentration of monomersMwt andM1 for
healthy (Fig. 4A) and unhealthy cells (Fig. 4B) for a range of concentration values. The perfor-
mance map (Fig. 4C) evidences that monomer combinations are not selective (i.e, P 0 at any
concentration). Isobolograms for Chwt and Ch1 combinations are shown for healthy (Fig. 4D)
and unhealthy (Fig. 4E) cell populations. The performance map (Fig. 4F) illustrates that the
combination shows regions of positive performance (P> 0), i.e., regions where the combinato-
rial treatment acts selectively towards the unhealthy cell population.
Performance colormaps for other combinations of chimeric drugs are shown in Fig. 5,
where regions in which the threshold of selectivity is achieved are marked in dark red. Simulta-
neous treatment of Chwt with Ch2, Ch3 and Ch4 show that, for each combination, optimal selec-
tivity can be achieved at slightly lower concentrations when using the two drugs
simultaneously, compared to the same drugs acting alone (i.e., [Chwt] = 0 in each panel). This
is more evident when combining Ch1 with the other chimeras (Fig. 5D–F), where the optimal
Fig 4. Isobolograms and performance colormaps for monomer and chimera combinations. (A–B) Isobolograms of the effect of the combination of
monomersMwt andM1 for (A) healthy and (B) unhealthy cells (final number of cells after 60 hours of treatment). (C) Performance of the combinatorial
monomer treatment, where all values are below 0, evidencing that the combination affects more strongly the healthy population. (D–E) Isobolograms of the
effect of chimerasChwt + Ch1 for (D) healthy and (E) unhealthy cells. (F) Performance of the combinatorial chimeric treatment, where all values are above 0,
evidencing that the combination affects more strongly the unhealthy population.
doi:10.1371/journal.pone.0117558.g004
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selectivity threshold is achieved at significantly lower concentrations using two selective drugs
instead of one (numerical values for the minimal concentration for the threshold of selectivity
as well as the reduction in total final concentration due to the combinatorial treatment are
shown in Table 2).
Synergistic interaction for selective chimeric drugs in cell populations
with heritability
Previous simulations assumed that both healthy and unhealthy cells are, as a first approxima-
tion, phenotypically different, with the expression levels of TER and AER obtained from
gamma distributions. Therefore, the amount of receptors expressed by a daughter cell depends
on its cell type, but it is independent on the amount of receptors expressed by the mother cell.
In other potential scenarios, the difference in phenotype between healthy and unhealthy cells
can be caused by genetic mutations, and therefore, the amount of receptors expressed by the
mother cell is inherited by the daughter cells. In these situations, a given treatment can become
inefficient, and it can potentially act as selective pressure, acting more strongly over weak cells
and ultimately inducing resistance to treatment in the population. This scenario has been ex-
plored extensively in vivo and in silico, and is one of the main causes of the short-lived response
Fig 5. Performance colormaps for different chimera combinations. (A–C) Combination of Chwt with other chimeras. (D–F) Combination of Ch1 with other
chimeras. Areas where the threshold of selectivity is achieved are marked in dark red. Since there is no negative values for the performance P, color bars are
now presented between 0 and 1.
doi:10.1371/journal.pone.0117558.g005
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of targeted therapy in cancer [18]. Recently, it has been shown theoretically and experimentally
that dual treatment strategies can dramatically reduce the possibility of development of resis-
tant cells, resulting in long-term disease control compared to single drug treatment, or even
sequential drug treatment [18].
To test the performance of dual selective treatment in the context of genetic inheritance of
the amount of receptors, we set the average amount of TER and AER expressed by a given
daughter cell as directly given by the amount of receptors expressed by the mother (with a
coefficient of variation of 0.3). Simulations are performed as in the previous section, and perfor-
mance colormaps can be computed for all possible concentrations of different ligand combina-
tions (Fig. 6). Comparison of Fig. 6A–F with the corresponding Fig. 5A–F evidences that
selectivity is more difficult to achieve in conditions of heritability (i.e., regions of optimal selec-
tivity (marked in dark red) are reduced and occur at higher concentrations). Numerical values
for the minimal concentration for the threshold of selectivity, as well as the reduction in total
final concentration due to the combinatorial treatment in conditions of heritability, are shown
in Table 3. Fig. 6 G–H, plots the values of AER and TER of the cells in the population before
(Fig. 6G) and after (Fig. 6H) 60 hours of treatment for the minimal concentration of Ch2 that
meets the threshold in conditions of heritability. Comparison of both distributions with condi-
tions of no heritability (Fig. 2J,M) evidences that heritability increases the variability in the ex-
pression levels of AER and TER in the population, resulting in a decrease in the performance of
the drug combinations and a reduction in the region of optimal selectivity (Fig. 6A–F).
Conclusions and Discussion
Chimeric ligands with selective potential constitute one of the forefronts in modern pharma-
cology. The development of strategies to affect only malfunctioning cells inside a healthy tissue
based on a sequential mechanisms of targeting is still in its early stages. Rational approaches
based on modulating the strength of the interaction between ligand and target has shown that
selectivity can be improved in a rational predictive manner [15, 25, 34]. Unfortunately, this
results in a marked increase of the total concentration of drug that needs to be administered,
which potentially increases the risk of toxicity and other undesired effects. Therefore, the prob-
lem of achieving selectivity at reduced drug concentrations is a main concern when developing
selective drugs.
Our previous modeling approaches [25, 34] allow us to predict the optimal value of the af-
finity and dissociation rates of both AE and TE for improved selectivity at the lowest drug con-
centration. Unfortunately, the affinity and dissociation rates in a given ligand-receptor
interaction cannot be modulated gradually, since single mutations in the ligand change abrupt-
ly the binding and unbinding rates with the complementary receptor. In this sense, combina-
tion of two ligands can, in principle, result beneficial to improve the selective potential of the
treatment since, for instance, highly potent ligands could affect cells expressing high TER con-
centrations, while more selective chimeras (i.e., with reduced potency in the AE subunit) could
discriminate better between healthy and unhealthy levels of the target protein.
To our knowledge, our results constitute the first studies focused on the combination of se-
lective drugs, by generalizing our previous results of single treatments with selective drugs [25]
to study selective drug combinations in cell population models. Our studies show that the com-
bination of selective drugs is synergistic in terms of their selective potential, i.e., the combina-
tion of selective drugs can reduce the total drug administered to achieve a given selective effect,
compared to the same drugs acting alone. We also show that using a explicit model of two
selective drugs is equivalent to a simplified model where the two drugs are assumed to interact
additively. This alternative method allows us to develop performance maps where selectivity is
Synergistic Interaction between Selective Drugs
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Fig 6. Performance colormaps for different chimera combinations in conditions of heritability. (A–C) Combination of Chwt with other chimeras. (D–F)
Combination of Ch1 with other chimeras. Areas where the threshold of selectivity is achieved are marked in dark red. Since there is no negative values for the
performance P, color bars are now presented between 0 and 1. (G–H) Distribution of the AER and TER receptors for the two cell populations before (G) and
after (H) 60 hours of treatment with Ch2 = 3 nM.
doi:10.1371/journal.pone.0117558.g006
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computed for any given concentration of the combined drugs. We used a cell population based
model to study how these types of treatments respond in a context of cell-variability and their
robustness in condition where the amount of target proteins is inherited from mother to
daughter cells. Interestingly, despite assuming additive interaction of the different chimeras
when combined (i.e., they compete for the same molecular targets), when looking at the selec-
tive potential of the treatment, chimeras behave as synergistic.
Several main assumptions are taken into account while developing the model. First, we as-
sume that production and degradation of each receptor is balanced in conditions of no ligand
stimulation. We also simplified all potential downstream regulation in receptor expression
after activation, focusing only on the regulation that takes place due to direct ligand stimula-
tion. We also assume that the activity triggered by the ligand-receptor interaction is propor-
tional to the amount of maximum active complexes formed. Other potential values such as the
total value of active complexes at a given time also produce equivalent results, as discussed in
[25] at the single cell level. Regarding the simulations of the population dynamics, we assumed
that all cells proliferate at the same mean rate, independently of the amount of EGFR receptors.
It is well-known that EGFR stimulation is correlated with the activation of proliferative signals
[32], but experimental data monitoring differences in cell cycle length for Daudi versus Daudi-
EGFR cells used to inform our model are not available [15]. In addition, the effect of heritabili-
ty in the expression of receptors was assumed to simply depend on the amount of receptors ex-
pressed by the mother cells. Other potential scenarios to capture the effect of mutations in the
regulation of the expression of receptors will be more realistic, but they will result in more free
parameters and assumptions. In addition, we assume that the effect of heritability will be more
relevant in longer experiments, i.e., when more generations of cells are allowed to develop. Un-
fortunately, experimental data are only available at the time point of t = 60h, corresponding to
an average of 2.2 generations, insufficient to observe the selective pressure effect induced by the
drug treatment. To mimic cell-to-cell variability in the population, we assumed gamma distri-
butions for the amount of receptors expressed and the cell cycle length, based on several publi-
cations. Other types of distributions were also tested (gaussian, lognormal), with almost no
difference in the results compared to the gamma distribution [35–38]. To quantitatively com-
pare the different combinatorial treatments, a threshold is defined in terms of the potential se-
lectivity of the treatment towards the different cell types expressing different concentrations of
the target proteins (80% survival of the healthy cells while the number of unhealthy cells is
maintained). Other potential threshold values defined also evidence the reported synergism
when combining two selective ligands, but at different drug concentrations.
In conclusion, we have shown that combination of selective drugs can selectively affect a
given cell population at reduced concentrations compared to single drug treatment. These
Table 3. Reduction in concentration at threshold for optimal selectivity in conditions of heritability.
Percentage of reduction of total drug concentration of combinatorial treatment versus single drug treatment
for different selective drug combinations.
Single drug Drug combination Reduction percentage
Ch2 = 2.9 Chwt + Ch2 = - -%
Ch3 = 5.3 Chwt + Ch3 = 4.5 15%
Ch4 = - Chwt + Ch4 = - -%
Ch2 = 2.9 Ch1 + Ch2 = 2.35 19%
Ch3 = 6 Ch1 + Ch3 = 3.45 42.5%
Ch4 = - Ch1 + Ch4 = - -%
doi:10.1371/journal.pone.0117558.t003
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types of theoretical studies focused on the rational design of selective drugs and treatments can
complement experimental efforts, allowing researches to develop a more reliable and efficient
approach to quantitative pharmacology.
Supporting Information
S1 Text. Response surface plots for drug interaction in conditions of drug additivity, syner-
gy or antagonism.
(TEX)
S1 Fig. Workflow to obtain the effect of a drug combination on a cell population. (A) Direct
simulation of two simultaneous treatments (see section Models: Eqs. 1–4 are solved directly for
two simultaneous ligands (j = 1,2) at a constant concentration. The value of AER-AE com-
plexes formed is then translated into a physiological effect using calibration with experimental
dose response curves obtained from [15]. Two populations of cells are defined with values for
AER and TER from gamma distributions for healthy and unhealthy cells. Eqs. 1–4 are solved
numerically for each cell in the two populations, obtaining the dynamics of growth for healthy
and unhealthy cell populations for a given constant concentration of L1 and L2. (B) Calculation
of the effect of combinatorial treatment assuming additive interaction between ligands: the
maximum number of AER-AE complexes is calculated for each combination of AER and TER
receptors concentrations by solving Eqs. 1–4 for a single ligand treatment (j = 1). The output of
the model is translated to a calibration curve [25], obtaining the theoretical dose-response
curves for each ligand. Physiological response curves are fitted to a four-parameter sigmoidal
(Eq.9), and the physiological response for any concentration of two ligands is then calculated
using the Loewe approximation for additive ligand interaction (Eq. 11). This response is then
used to perform simulations for healthy and unhealthy cell populations, following the same
procedure as in (A). Finally, the number of healthy and unhealthy cells after 60 hours of treat-
ment is plotted in the corresponding isobologram for each ligand combination. The final per-
formance colormap for each value of the combination of ligands is obtained by subtracting the
normalized isobolograms for unhealthy minus healthy cells. Values above threshold of perfor-
mance are highlighted in dark red.
(TIFF)
S2 Fig. Dynamics of the cell populations after individual monomer treatment. Numerical
solution of the model equations showing the time evolution of healthy (blue line) and un-
healthy (red line) cells after treatment with low, intermediate and high concentrations of
(A–C)M1 monomer, (D–F)M2 monomer, and (G–I)M3 monomer.
(TIFF)
S3 Fig. Dynamics of the cell populations after individual chimeric treatment.Numerical so-
lution of the model equations showing the time evolution of healthy (blue line) and unhealthy
(red line) cells after treatment with low, intermediate and high concentrations of (A–C) Ch1
chimera, (D–F) Ch3 chimera, and (G–I) Ch4 chimera.
(TIFF)
S4 Fig. Response surfaces for L1 + L2 combinations. Response surface plots using Eq.13 (see
S1 Text) for two ligands showing (A) additivity, α = 0, (B) synergy, α = 5 and (C) antagonism,
α = −0.5. The black curve is the isobol curve (i.e., curve of equal effect) for 50% (EC50) of physi-
ological response and it has different curvature depending on the interaction type.
(TIFF)
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S5 Fig. Numerical solution of the model equations showing synergistic performance of se-
lective ligands using the Loewe approximation (to be compared with Fig. 3 in the main
text, obtained using chemical dynamics simulation of two ligands simultaneously). (A–C)
Time evolution of healthy (blue line) and unhealthy (red line) cells after treatment with differ-
ent combinations of monomers, at the minimal concentration required to affect 20% of the un-
healthy cell population. (D–F) Time evolution of different combinations of Chwt with other
chimeric ligands at the minimal concentration required to achieve the threshold for selectivity.
(G–I) Time evolution of different combinations of Ch1 with other chimeric ligands at the mini-
mal concentration required to achieve the threshold for selectivity.
(TIFF)
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